Redeye comments on CLS’s directed issue, raising up to SEK37m.
Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent ap...
IPU ramp-up delayed: we cut '25e-'26e revenue by 44-33% UPF partnerships opens a large new segment T...
Redeye provides a research update following the Q4 report published by Alzinova earlier today.
Voi, som är VNV Globals näst största innehav, kom med en stark Q4-rapport.
Redeye's provides its initial take on Oncopeptides’ year-end report, which came in slightly softer t...
Redeye provides an initial comment on the Q4 2024 report from Serstech.
Solwers’ Q4 sales of EUR 21.7m were fairly in line with our estimate of EUR 22.
Redeye comments on W5 Solutions Q4-results where sales were in line with expectations while EBITDA w...
Føroya Banki reported a soft Q4, as profit before loan losses landed at DKK 46m, DKK 8m (6%) below o...
Redeye provides a research update following the Q4 report published by Lipum earlier today.
Analyst Group initiates equity research coverage on HydrogenPro (“HydrogenPro” or “the Company”), wh...
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) är en konsultgrupp inom samhällsbyggnad, vilka...
Redeye comments on Alligator Bioscience’s 24-month survival numbers, which are superior to historica...
Redeye comments on yesterday’s news from Nitro Games, announcing that Netflix has canceled its proje...
Q4 profit before loan losses came in at DKK 46m, DKK 8m (6%) below our estimate.
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) är en ledande friskolekoncern med verksamhet från...
Även om vi bibehåller vår positiva syn på Elon inför 2025 och framåt har vi sänkt våra förväntningar...
Another year with raised DPS (16th year of the last 22 years) Q4 sales miss (0% org growth), but adj...
Lönsamhet och starkt kassaflöde Nettoomsättningen minskade med 8,2 procent, drivet av en fortsatt ut...
